Bimzelx (bimekizumab-bkzx) — Highmark
Plaque Psoriasis (PsO)
Initial criteria
- age ≥ 18 years
- diagnosis of moderate to severe plaque psoriasis (PsO)
- prescribed by or in consultation with a dermatologist or rheumatologist
- therapeutic failure or intolerance to phototherapy (e.g., PUVA, UVB) OR to at least one systemic therapy (e.g., methotrexate) OR contraindicated to both phototherapy and systemic therapy
- therapeutic failure or intolerance to at least one step 1 plan-preferred agent for the treatment of PsO
Reauthorization criteria
- disease stability or beneficial response to therapy